InnoCare Pharma (SHA:688428, HKG:9969) booked an attributable net profit of 246.4 million yuan in the first half of 2026, returning from a loss of 30.1 million yuan a year ago.
Earnings per share stood at 0.14 yuan per share, compared with loss per share of 0.02 yuan per share, according to a Hong Kong bourse disclosure on Monday.
The pharmaceutical company's revenue jumped 55.5% to 1.14 billion yuan from 731.4 million yuan a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.